“Steroid-Refractory Chronic Graft-versus-Host Disease Treated with Ruxolitinib: A Narrative Review of Symptom Burden and Return to Daily Life” (2023) Journal of Clinical Case Studies and Reviews, 4(1), pp. 31–36. doi:10.5281/zenodo.22227762.